Cargando…

Effect of Ions and Sequence Variants on the Antagonist Binding Properties of the Histamine H(1) Receptor

The histamine H(1) receptor (H(1)R) is a G protein-coupled receptor (GPCR) and represents a main target in the treatment of allergic reactions as well as inflammatory reactions and depressions. Although the overall effect of antagonists on H(1) function has been extensively investigated, rather litt...

Descripción completa

Detalles Bibliográficos
Autores principales: Conrad, Marcus, Söldner, Christian A., Sticht, Heinrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836275/
https://www.ncbi.nlm.nih.gov/pubmed/35163341
http://dx.doi.org/10.3390/ijms23031420
Descripción
Sumario:The histamine H(1) receptor (H(1)R) is a G protein-coupled receptor (GPCR) and represents a main target in the treatment of allergic reactions as well as inflammatory reactions and depressions. Although the overall effect of antagonists on H(1) function has been extensively investigated, rather little is known about the potential modulatory effect of ions or sequence variants on antagonist binding. We investigated the dynamics of a phosphate ion present in the crystal structure and of a sodium ion, for which we determined the position in the allosteric pocket by metadynamics simulations. Both types of ions exhibit significant dynamics within their binding site; however, some key contacts remain stable over the simulation time, which might be exploited to develop more potent drugs targeting these sites. The dynamics of the ions is almost unaffected by the presence or absence of doxepin, as also reflected in their small effect (less than 1 kcal·mol(−1)) on doxepin binding affinity. We also examined the effect of four H(1)R sequence variants observed in the human population on doxepin binding. These variants cause a reduction in doxepin affinity of up to 2.5 kcal·mol(−1), indicating that personalized medical treatments that take into account individual mutation patterns could increase precision in the dosage of GPCR-targeting drugs.